Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EMERSON ELECTRIC COEMR · Entity 2942 | Director | November 08, 2023 | November 13, 2023 |
| Turn Therapeutics Inc.TTRX · Entity 5935 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EMERSON ELECTRIC CO
Report date November 08, 2023 · Filed November 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 97,504 |
Reported balance
After 2023-11-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-11-08 · Purchase · Acquired 3,000 · Balance 97,504 F1: Includes 1,424 shares acquired under a dividend reinvestment plan since the Reporting Person's last Form 4 filing. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,424 shares acquired under a dividend reinvestment plan since the Reporting Person's last Form 4 filing.
Turn Therapeutics Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2036-06-04 | Direct | 89,584 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 89,584 · Balance 89,584 F1: The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 21:30 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | GrantStock option (right to buy) · Derivative | 89,584 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001213900-26-066393 · ownership.xml · derivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,584 Underlying: Common Stock · 89,584 shares Expires 2036-06-04 F1 · derivative.exercise_date: The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 12:08 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | GiftCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-039714 · ownership.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,602 Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 02:00 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | PurchaseCommon Stock | 9,868 | $3.44 | $33,945.92 |
DisclosureSEC source: 0001213900-25-114990 · ownership.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,602 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.50, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F1 · balance_after: Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 12:13 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | PurchaseCommon Stock | 20,532 | $2.87 | $58,926.84 |
DisclosureSEC source: 0001213900-25-113841 · ownership.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,734 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.66 to $3.25, inclusive. The Reporting Person undertakes to provide to Turn Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F1 · balance_after: Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 01:01 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | PurchaseCommon Stock | 20,202 | $4.95 | $99,999.90 |
DisclosureSEC source: 0001104659-25-101923 · tm2529397-1_4seq1.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,202 F1 · balance_after: Certain of the securities reported in Column 5 of Table I are restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and the reporting person's continuous service through the vesting date. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 13:41 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-098568 · tm2528487-2_4seq1.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · security: Reflects an award of restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs will vest upon the earlier of the first anniversary of the grant date or a change in control of the Issuer, in each case, subject to the reporting person's continuous service through the vesting date. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 13:13 UTC | EMERSON ELECTRIC CO EMR · Entity 2942 | PurchaseCommon Stock | 3,000 | $85.64 | $256,920.00 |
DisclosureSEC source: 0001062993-23-020512 · form4.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,504 F1 · balance_after: Includes 1,424 shares acquired under a dividend reinvestment plan since the Reporting Person's last Form 4 filing. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:57 UTC | EMERSON ELECTRIC CO EMR · Entity 2942 | GrantCommon Stock | 1,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-23-000035 · edgar.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,081 F1 · kind: Grant to Reporting Person of 1,933 restricted stock units having a fair market value of $90.5250 per unit on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F1 · shares: Grant to Reporting Person of 1,933 restricted stock units having a fair market value of $90.5250 per unit on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F2 · price: Price is not applicable to acquisitions resulting from grants of restricted stock units. F3 · balance_after: Includes 1,807 shares acquired under a dividend reinvestment plan since the Reporting Person's last Form 4 filing. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 20:44 UTC | EMERSON ELECTRIC CO EMR · Entity 2942 | GrantCommon Stock | 1,905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-22-000048 · edgar.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,341 F1 · kind: Grant to Reporting Person of 1,905 shares of restricted stock having a fair market value of $91.83 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F1 · shares: Grant to Reporting Person of 1,905 shares of restricted stock having a fair market value of $91.83 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F2 · price: Price is not applicable to acquisitions resulting from grants of restricted stock. F3 · balance_after: Includes 1,601 shares acquired under a dividend reinvestment plan since the Reporting Person's last Form 4 filing. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:49 UTC | EMERSON ELECTRIC CO EMR · Entity 2942 | GrantCommon Stock | 1,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-21-000103 · edgar.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,835 F1 · kind: Grant to Reporting Person of 1,787 shares of restricted stock having a fair market value of $83.905 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F1 · shares: Grant to Reporting Person of 1,787 shares of restricted stock having a fair market value of $83.905 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F2 · price: Price is not applicable to acquisitions resulting from grants of restricted stock. F3 · balance_after: Includes 2,150 shares acquired under a dividend reinvestment plan since the Reporting Person's last Form 4 filing. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 15:18 UTC | EMERSON ELECTRIC CO EMR · Entity 2942 | PurchaseCommon Stock | 5,000 | $51.47 | $257,346.00 |
DisclosureSEC source: 0000950138-20-000164 · edgar.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,898 F1 · price: The price in column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $51.465 to $51.47. The Reporting Person undertakes to provide Emerson Electric Co., any securityholder of Emerson Electric Co. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote, Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 21:46 UTC | EMERSON ELECTRIC CO EMR · Entity 2942 | GrantCommon Stock | 2,030 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-20-000076 · edgar.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,898 F1 · kind: Grant to Reporting Person of 2,030 shares of restricted stock having a fair market value of $73.865 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F1 · shares: Grant to Reporting Person of 2,030 shares of restricted stock having a fair market value of $73.865 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F2 · price: Price is not applicable to acquisitions resulting from grants of restricted stock. F3 · balance_after: Includes 1,833 shares acquired under a dividend reinvestment plan since the Reporting Person's last Form 4 filing. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 21:24 UTC | EMERSON ELECTRIC CO EMR · Entity 2942 | GrantCommon Stock | 2,264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-19-000075 · edgar.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,035 F1 · kind: Grant to Reporting Person of 2,264 shares of restricted stock having a fair market value of $66.24 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F1 · shares: Grant to Reporting Person of 2,264 shares of restricted stock having a fair market value of $66.24 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F2 · price: Price is not applicable to acquisitions resulting from grants of restricted stock. F3 · balance_after: Includes 1,624 shares acquired under a dividend reinvestment plan since the Reporting Person's last Form 4 filing. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 15:37 UTC | EMERSON ELECTRIC CO EMR · Entity 2942 | GrantCommon Stock | 2,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-18-000121 · edgar.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,147 F1 · kind: Grant to Reporting Person of 2,038 shares of restricted stock having a fair market value of $68.69 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F1 · shares: Grant to Reporting Person of 2,038 shares of restricted stock having a fair market value of $68.69 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F2 · price: Price is not applicable to acquisitions resulting from grants of restricted stock. F3 · balance_after: Includes 1,714 shares acquired under a dividend reinvestment plan since the Reporting Person's last Form 4 filing. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 20:32 UTC | EMERSON ELECTRIC CO EMR · Entity 2942 | GrantCommon Stock | 2,248 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-17-000142 · edgar.xml · nonDerivative · entry 1 GOLDEN ARTHUR F · CIK 0001023260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,395 F1 · kind: Grant to Reporting Person of 2,248 shares of restricted stock having a fair market value of $62.26 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F1 · shares: Grant to Reporting Person of 2,248 shares of restricted stock having a fair market value of $62.26 per share on the date of grant under shareholder approved benefit plan pursuant to Rule 16b-3(d). F2 · price: Price is not applicable to acquisitions resulting from grants of restricted stock. F3 · balance_after: Includes 1,831 shares acquired under a dividend reinvestment plan since the Reporting Person's last Form 4 filing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.